NCT05986864 - Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 23, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 30, 2026

Conditions

Neovascular Age-related Macular Degeneration

Interventions

GENETIC

SKG0106

SKG0106 is a recombinant adeno-associated virus (AAV) vector-based in vivo gene therapeutic product

Trial Locations (9)

RECRUITING

Wagner Kapoor Research Institute, Norfolk

NOT_YET_RECRUITING

Retina Vitreous Associates of Florida - Saint Petersburg, St. Petersburg

RECRUITING

Retina Consultants of Texas, Katy

RECRUITING

Ophthalmic Consultants of Boston, Boston

RECRUITING

The Second Hospital Of Anhui Medical University, Hefei

RECRUITING

Zhejiang Provincial People's Hospital, Hangzhou

RECRUITING

Eye Hospital, WMU (Zhejiang Eye Hospital), Wenzhou

RECRUITING

Beijing Hospital, Beijing

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors

lead

Skyline Therapeutics (US) Inc.

INDUSTRY